Product Launch
Design Therapeutics initiates Phase 1 trial dosing of DT-818 for Myotonic Dystrophy Type-1
June 30, 2026
Biotech
Product Launch
Key Facts
Signal Type
Product Launch
Industry
Biotech
Companies
Design Therapeutics, Inc.
Date
June 30, 2026
Design Therapeutics announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) trial for DT-818, a GeneTAC® small molecule targeting Myotonic Dystrophy Type-1 (DM1). The open-label study will assess safety, tolerability, pharmacokinetics, and pharmacodynamic effects, with data anticipated in 2027.
DM1 is a progressive neuromuscular disease affecting over 70,000 people in the U.S., caused by a DMPK gene mutation. Patients experience muscle weakness, cardiac arrhythmias, and neuropsychological changes. DT-818 aims to address the root cause by selectively reducing transcription of the mutant allele.
Key milestones include 2027 Phase 1 data readout and progression to later-stage trials. Competitive differentiation will hinge on DT-818's ability to demonstrate superior pharmacodynamics versus RNA-targeting approaches in development.
Source:
The Manila TimesGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
